Skip to content

Vitamin D and Cardiovascular Events in Rheumatoid Arthritis

Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02932644
Enrollment
160
Registered
2016-10-13
Start date
1999-10-31
Completion date
2016-10-31
Last updated
2016-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, Cardiovascular event, Cardiovascular mortality, Vitamin D

Brief summary

The aim of the study is to evaluate cardiovascular events during long-term follow-up in Rheumatoid Arthritis. The primary outcome any cardiovascular event will be evaluated using systematic audits of patient records, and will be associated to low levels of vitamin D at baseline, to investigate the hypothesis that low levels of vitamin D can be part of a prediction model for cardiovascular disease in Rheumatoid Arthritis.

Detailed description

Cardiovascular morbidity and mortality is increased in patients with rheumatoid arthritis (RA), and among these patients, the prevalence of hypo-vitaminosis D is high. Low levels of vitamin D have been associated with elevated cardiovascular risk in healthy subjects. The objective of this study is to evaluate the risk of cardiovascular events in patients having low 25OHD-total levels at baseline compared to patients with sufficient levels, in an aggressively treated closed cohort of early-diagnosed RA patients. The primary outcome will be the proportion of patients with any cardiovascular event, evaluated using systematic journal audits. Logistic regression models will be applied to test the hypothesis that there are more cardiovascular events in patients enrolled with a low level of vitamin D (\< 50 nmol/l). Secondarily, Cox regression models, based on survival analysis, will be applied, to determine the extent to which independent variables (including different levels of vitamin D at baseline) predict not only whether a cardiovascular event occur, but also when it will occur.

Interventions

OTHERBaseline serum vitamin D level below 50 nmol/l

There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis

OTHERBaseline serum vitamin D level at or above 50 nmol/l

There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis

Sponsors

The Danish Rheumatism Association
CollaboratorOTHER
University of Southern Denmark
CollaboratorOTHER
Region of Southern Denmark
CollaboratorOTHER
Pfizer
CollaboratorINDUSTRY
Odense Patient Data Explorative Network
CollaboratorOTHER
Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Fulfilling ACR1987 (American College of Rheumatology 1987 classification criteria for Rheumatoid Arthritis) criteria for RA, disease duration \< 6 months, 2 or more swollen joints and age between 18 and 75 years -

Exclusion criteria

Glucocorticoid treatment 4 weeks prior to inclusion, previous use of DMARDs, malignancy, diastolic blood pressure \> 90 mm Hg, elevated serum creatinine, infections with parvovirus B19, Hepatitis B, C and HIV, and any condition contraindicating the study medication. \-

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular eventObserved in the time-period from inclusion to October the 10th 2016Events will be recorded using systematic journal audits. A cardiovascular event will be further subclassified as shown in the secondary outcome measures, but for primary outcome measures; any cardiovascular event, including death, will serve as an event

Secondary

MeasureTime frameDescription
Acute cardiovascular hospitalisation due to Myocardial IschamiaObserved in the time-period from inclusion to October the 10th 2016Non-fatal or fatal myocardial infarction, defined by National and International Guidelines (Thygesen et al. 1581-98). Fatal myocardial infarction is defined as primary fatal event within 7 days, documented post mortem by autopsy, or by the definition of myocardial infarction according to European Guidelines (Thygesen et al. 1581-98) Death of myocardial infarction as a consequence of medical examination/procedure/surgery will be classified as procedure related death. Acute Coronary Syndrome (ACS) includes acute ischaemic symptoms with eventual elevation in biomarkers or electrocardiographic changes which does not fulfil the criteria of acute myocardial infarction. Angina Pectoris. Revascularisation procedures (Percutaneous Coronary Intervention (PCI) or Coronary bypass Graft (CABG).
Acute cardiovascular hospitalisation due to hearth failureObserved in the time-period from inclusion to October the 10th 2016Patients with non-elective hospitalisation or death, minimum one overnight stay, with symptoms or findings of heart failure. Death due to heart failure is defined as escalating heart failure symptoms prior to death.
Acute cardiovascular hospitalisation due to strokeObserved in the time-period from inclusion to October the 10th 2016Cerebral haemorrhage, cerebral thromboembolism, Transitory Cerebral Ischemia (TCI) and others Stroke is defined as abrupt severe neurologic deficits, eventually with computer tomographic (CT) documentation. Death within 14 days after symptom-onset of stroke, and without other obviously reasons, is classified as caused by stroke
Acute non-cardiovascular hospitalisation due to traumaObserved in the time-period from inclusion to October the 10th 2016Acute hospitalisation due to trauma
Acute cardiovascular hospitalisation due to arrhythmiasObserved in the time-period from inclusion to October the 10th 2016Atrial fibrillation or flutter, supraventricular tachycardia and others. Ventricular tachycardia, ventricular fibrillation and others. Death due to arrhythmia requires documentation, e.g. telemetric transcript, pacemaker or electrocardiogram
Acute cardiovascular hospitalisation due to Procedure-related cardiovascular eventObserved in the time-period from inclusion to October the 10th 2016Any cardiovascular event within 24 hours after cardiovascular medical examination/procedure/surgery.
Acute cardiovascular hospitalisation due to other reasonsObserved in the time-period from inclusion to October the 10th 2016Hospitalisation caused by other cardiovascular events, e.g. pulmonary embolism, rupture of aortic aneurism etc.
Acute cardiovascular hospitalisation due to supposed cardiovascular reasonObserved in the time-period from inclusion to October the 10th 2016Hospitalisation without any documented non-cardiovascular cause. All deaths which are not defined by the cardiovascular reasons mentioned above, and who are not caused by well-documented non-cardiovascular death. All deaths without known reason
Acute non-cardiovascular hospitalisation due to cancerObserved in the time-period from inclusion to October the 10th 2016Acute hospitalisation due to cancer
Acute non-cardiovascular hospitalisation due to infectionObserved in the time-period from inclusion to October the 10th 2016Acute hospitalisation due to infection
Acute non-cardiovascular hospitalisation due to suicideObserved in the time-period from inclusion to October the 10th 2016Acute - hospitalisation due to suicide
Acute non-cardiovascular hospitalisation due to other reasonsObserved in the time-period from inclusion to October the 10th 2016Acute hospitalisation du to other non-cardiovascular reasons, than those previous mentioned
Acute non-cardiovascular hospitalisation due to respiratory diseaseObserved in the time-period from inclusion to October the 10th 2016Acute hospitalisation due to respiratory disease
Elective cardiovascular hospitalisation due to arrhythmiaObserved in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to heart failureObserved in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to other cardiovascular reasonsObserved in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to cancerObserved in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to infectionObserved in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to respiratory diseaseObserved in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to traumaObserved in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to suicideObserved in the time-period from inclusion to October the 10th 2016
Witnessed, sudden cardiovascular deathObserved in the time-period from inclusion to October the 10th 2016Death is witnessed and abrupt within one hour after symptom-onset
Non-witnessed, sudden cardiovascular deathObserved in the time-period from inclusion to October the 10th 2016Non-witnessed death with no obvious non-cardiovascular reasons (found death)
Non-sudden cardiovascular deathObserved in the time-period from inclusion to October the 10th 2016Death due to any of the cardiovascular caused previously mentioned, more than one hour after symptom-onset
Elective cardiovascular hospitalisation due to myocardial ischemiaObserved in the time-period from inclusion to October the 10th 2016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026